



ForgingBridges Free Trial Program

Help your eligible patients start Attruby™ with the Free Trial Program

Your patients may be eligible for the Free Trial Program, which provides a 1-month supply of Attruby at no cost. The Free Trial Program is available to eligible patients with any form of insurance who are new to Attruby. See full Terms and Conditions below.

To get your patient started:



Fill out the attached

Free Trial Form for your patient



Sign and date where indicated



Fax the completed form to **1-877-738-0545**

Questions? Call ForgingBridges at

1-888-55-BRIDGE (1-888-552-7434)

Mon-Fri, 8 AM to 8 PM ET or visit ForgingBridges.com

Free Trial Program Terms and Conditions

The ForgingBridges Free Trial Program ("FTP"), sponsored by BridgeBio Pharma Inc. ("BridgeBio"), the manufacturer of Attruby, provides a 1-month supply of Attruby at no cost to patients who meet FTP eligibility requirements and who agree to the FTP terms and conditions by submitting a signed FTP start form. FTP is a free trial offer, intended solely to allow new patients to try Attruby and to determine with their healthcare provider whether Attruby is right for them. There is no obligation to continue use of Attruby after the free trial has been completed. To be eligible, a patient must: (1) reside in the United States or Puerto Rico; (2) have a valid prescription for Attruby for an FDA-approved indication; and (3) be a new patient not currently using Attruby and who has not previously filled a prescription for or received a sample of Attruby, or received Attruby through the FTP. Attruby supplied through the FTP will (i) be dispensed only by a pharmacy designated by BridgeBio; (ii) be delivered only to the patient's home address (no P.O. boxes) and (iii) not exceed a 1-month supply. It is unlawful for any person to sell, purchase, trade, barter, or export Attruby supplied through the FTP or make an offer to do so. Patients, pharmacists, and prescribers may not seek reimbursement, either directly or indirectly, for Attruby supplied through the FTP from health insurance or any third-party payer, including Medicare, Medicaid, and commercial insurance plans. Patients must not count the value of the FTP product as an expense incurred for purposes of determining patient out-of-pocket costs under any health insurance program, including Medicare Part D True Out-of-Pocket Costs ("TrOOP"). For patients with Medicare Part D coverage, Forging Bridges will notify the patient's Medicare Part D plan that the patient is enrolled in the FTP and will be receiving Attruby at no cost outside of the Medicare Part D benefit. The FTP does not provide health insurance and is not a discount, rebate, coupon, cost-sharing program, or other form of financial assistance. Obtaining Attruby through the FTP is not contingent on any past, present, or future purchase of Attruby. This offer is limited to one use per patient per lifetime and is non-transferable. To continue a patient on therapy after such one-time use, a separate prescription must be written by the healthcare provider. Use of the FTP is void where prohibited by law and where use is prohibited by the patient's insurance provider. BridgeBio reserves the right to rescind, revoke, or amend the FTP at any time without notice.

Please see full Prescribing Information for Attruby at Attruby.com/Pl.





Free Trial Program Form

Please fax this page to 1-877-738-0545

PATIE				
irst Name:		Presc	riber Name:	
	Gender: Male			
ddress:				
ity:	State: ZIP:	: Facili	ty Name:	
Nobile Phone:		Addre	ess:	
lternate Phone:				State: ZIP:
mail Address:		Office	Contact Name:	
lternate Contact/Caregiv	er Name:	Phon	e:	
hone:		Email	Address:	
elationship to Patient:		Fax: _		
	CI	LINICAL INFORM	ATION	
 New to Attruby™ (requ				
New to Attrably (requ	inca)			
CD-10-CM Diagnosis Cod	e (select one)*:			
E85.4: Organ-limited	E85.82: Wild-type transthy		dosis, Other:	
0			dosis, Other:	
E85.4: Organ-limited amyloidosis	E85.82: Wild-type transthy	s unspecified	<u> </u>	
E85.4: Organ-limited amyloidosis	E85.82: Wild-type transthy related (ATTR) amyloidosi Known Drug Allergies:	s unspecified	<u> </u>	
E85.4: Organ-limited amyloidosis fledication Allergies:	E85.82: Wild-type transthy related (ATTR) amyloidosi Known Drug Allergies:	s unspecifiéd		No Known Allerg
E85.4: Organ-limited amyloidosis Medication Allergies: Furrent or Previous Thera Tafamidis Dose:	E85.82: Wild-type transthy related (ATTR) amyloidosi Known Drug Allergies:	s unspecifiéd Tafamidis me	eglumine Dose:	No Known Allerg
E85.4: Organ-limited amyloidosis Medication Allergies: Furrent or Previous Thera Tafamidis Dose:	E85.82: Wild-type transthy related (ATTR) amyloidosi Known Drug Allergies: py: Duration: Dose:	s unspecifiéd Tafamidis me	eglumine Dose: \(\square\) No	No Known Allerg
E85.4: Organ-limited amyloidosis Medication Allergies: Turrent or Previous Thera Tafamidis Dose: Other:	E85.82: Wild-type transthy related (ATTR) amyloidosi Known Drug Allergies: py: Duration: Dose: PRES	Tafamidis me Duration:	eglumine Dose: \(\square\) No	□ No Known Allerg □ Duration: □
E85.4: Organ-limited amyloidosis Medication Allergies: Turrent or Previous Thera Tafamidis Dose: Other:	E85.82: Wild-type transthy related (ATTR) amyloidosi Known Drug Allergies: py: Duration: Dose:	Tafamidis me Duration:	eglumine Dose: \(\square\) No	□ No Known Allerg □ Duration: □
E85.4: Organ-limited amyloidosis Medication Allergies: Turrent or Previous Thera Tafamidis Dose: Other:	E85.82: Wild-type transthy related (ATTR) amyloidosi Known Drug Allergies: py: Duration: Dose: PRES available to eligible patients with	Tafamidis me Duration:	eglumine Dose: No	□ No Known Allerg □ Duration: □
E85.4: Organ-limited amyloidosis Medication Allergies: Turrent or Previous Thera Tafamidis Dose: Other:	E85.82: Wild-type transthy related (ATTR) amyloidosi Known Drug Allergies: py: Duration: Dose: PRES available to eligible patients with	Tafamidis me Duration: SCRIPTION INFOR	eglumine Dose: No	□ No Known Allerg □ Duration: □
E85.4: Organ-limited amyloidosis Medication Allergies: Tafamidis Dose: Other: The Free Trial Program is	E85.82: Wild-type transthy related (ATTR) amyloidosi Known Drug Allergies: py: Duration: Dose: PRES available to eligible patients with mme	Tafamidis me Duration: SCRIPTION INFOR any form of insurance who	eglumine Dose: No RMATION are new to Attruby. For full ription	No Known Allerg Duration: one Ferms and Conditions, see Page 1
E85.4: Organ-limited amyloidosis Medication Allergies: Tafamidis Dose: Other: The Free Trial Program is Orug Na Attruby 356 m NDC: 82228	E85.82: Wild-type transthy related (ATTR) amyloidosi Known Drug Allergies: py: Duration: Dose: PRES available to eligible patients with mme	Tafamidis me Duration: SCRIPTION INFOR any form of insurance who Attruby Free Trial Prescring Instructions tablets by mouth twice daily	eglumine Dose: RMATION are new to Attruby. For full fiption Quantity Dispense 28-day supply	Duration: Duration: Perms and Conditions, see Page 1 Refills O refills
E85.4: Organ-limited amyloidosis Medication Allergies: Tafamidis Dose: Other: The Free Trial Program is Orug Na Attruby 356 m NDC: 82228	E85.82: Wild-type transthy related (ATTR) amyloidosi Known Drug Allergies: py: Duration: PRES available to eligible patients with me Dosi gtablets Take 2 -712-28	Tafamidis me Duration: SCRIPTION INFOR any form of insurance who Attruby Free Trial Prescring Instructions tablets by mouth twice daily	eglumine Dose: RMATION are new to Attruby. For full fiption Quantity Dispense 28-day supply 1043877996), RareMed will	Duration: Duration: Perms and Conditions, see Page 1 Refills O refills

My signature certifies that the patient named on this form is my patient, that the information provided by me in the form is, to the best of my knowledge, complete and accurate, and that therapy with Attruby is medically necessary for my patient. I certify that I have obtained from my patient written authorization, in accordance with all applicable state and federal law, to release the patient's individually identifiable health information included on this form to ForgingBridges and that such authorization permits ForgingBridges to contact the patient and otherwise the patient's individually identifiable information to (i) verify my patient's insurance coverage (including by sharing the information with the patient's insurance plan); (ii) determine my patient's eligibility for ForgingBridges benefits; and (iii) coordinating ForgingBridges programs for the benefit of my patient. For specialty pharmacy prescriptions, I authorize ForgingBridges to transmit the above prescription to the appropriate specialty pharmacy for my patient. I understand I am under no obligation to prescribe any BridgeBio product, and I certify that I have not received, nor will I receive, any benefit from BridgeBio for doing so. I understand that completing this enrollment form does not guarantee that assistance will be provided to my patient. I will not seek reimbursement for any medication dispensed under the ForgingBridges program from any third-party payer, patient, or other person or entity. Any medication I receive on behalf of my patient from ForgingBridges will be appropriately secured and stored until it is dispensed at no charge to the above-named patient only, and will not be resold nor offered for sale, trade, or barter and will not be returned for credit. I agree to comply with and abide by all applicable state practitioner dispensing laws for authorized prescribers. I attest I am not on the HHS/OIG list of excluded individuals. I understand that BridgeBio

Special Note: New York prescriber, please use an original New York State prescription form. The prescriber is to comply with the prescriber's state-specific prescription requirements. HHS=US Department of Health and Human Services; ICD-10-CM=International Classification of Diseases, Tenth Revision, Clinical Modification; NDC=National Drug Code; NPI=National Provider Identifier; OIG=Office of Inspector General.

Please see full Prescribing Information for Attruby at Attruby.com/PI.



reserves the right to rescind, revoke, or amend the program and to discontinue support at any time without notice.